Research Summary
Benign Prostatic Hyperplasia (BPH) drugs are medications used in the treatment of an enlarged prostate gland, a condition known as benign prostatic hyperplasia. BPH is a common condition in older men that can cause bothersome urinary symptoms such as frequent urination, weak urine flow, and the need to urinate during the night. BPH drugs work by targeting the underlying mechanisms that contribute to prostate enlargement, such as reducing the production or blocking the action of hormones that promote prostate growth. Common classes of BPH drugs include alpha-blockers, which relax the muscles in the prostate and bladder neck to improve urine flow, and 5-alpha-reductase inhibitors, which inhibit the conversion of testosterone to dihydrotestosterone, a hormone that promotes prostate growth. These medications can help alleviate urinary symptoms, improve urinary flow, and reduce the risk of complications associated with BPH. The choice of BPH drug depends on factors such as the severity of symptoms, prostate size, patient preferences, and overall health. It is important to consult with a healthcare professional for proper evaluation, diagnosis, and determination of the most appropriate BPH treatment approach.
According to DIResearch's in-depth investigation and research, the global Benign Prostatic Hyperplasia (BPH) Drugs market size will reach US$ XX Million in 2024, and is expected to reach US$ XX Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be US$ XX Million, accounting for approximately XX% of the world. It is expected to reach US$ XX Million in 2030, and the global share will reach XX%.
The major global manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Abbott, Pfizer, TEVA, Allergan, Mylan, Novartis, Merck etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.
This report studies the market size, price trends and future development prospects of Benign Prostatic Hyperplasia (BPH) Drugs. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Benign Prostatic Hyperplasia (BPH) Drugs market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Benign Prostatic Hyperplasia (BPH) Drugs market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Benign Prostatic Hyperplasia (BPH) Drugs industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs Include:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Abbott
Pfizer
TEVA
Allergan
Mylan
Novartis
Merck
Benign Prostatic Hyperplasia (BPH) Drugs Product Segment Include:
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Benign Prostatic Hyperplasia (BPH) Drugs Product Application Include:
Hospitals
Drugstores
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Benign Prostatic Hyperplasia (BPH) Drugs Industry PESTEL Analysis
Chapter 3: Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Porter's Five Forces Analysis
Chapter 4: Global Benign Prostatic Hyperplasia (BPH) Drugs Major Regional Market Size and Forecast Analysis
Chapter 5: Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Benign Prostatic Hyperplasia (BPH) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Benign Prostatic Hyperplasia (BPH) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Benign Prostatic Hyperplasia (BPH) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Benign Prostatic Hyperplasia (BPH) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Benign Prostatic Hyperplasia (BPH) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Benign Prostatic Hyperplasia (BPH) Drugs Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
Table of Contents 1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview 1.1 Product Definition and Statistical Scope 1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product by Type 1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type, 2023 VS 2024 VS 2030 1.2.2 Alpha-Blocker 1.2.3 Phosphodiesterase Type-5 Inhibitors 1.2.4 Others 1.3 Benign Prostatic Hyperplasia (BPH) Drugs Product by Application 1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application, 2023 VS 2024 VS 2030 1.3.2 Hospitals 1.3.3 Drugstores 1.3.4 Others 1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Revenue Analysis (2019-2030) 1.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Development Status and Trends 1.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Development Status Analysis 1.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Development Trends Analysis 2 Benign Prostatic Hyperplasia (BPH) Drugs Market PESTEL Analysis 2.1 Political Factors Analysis 2.2 Economic Factors Analysis 2.3 Social Factors Analysis 2.4 Technological Factors Analysis 2.5 Environmental Factors Analysis 2.6 Legal Factors Analysis 3 Benign Prostatic Hyperplasia (BPH) Drugs Market Porter's Five Forces Analysis 3.1 Competitive Rivalry 3.2 Threat of New Entrants 3.3 Bargaining Power of Suppliers 3.4 Bargaining Power of Buyers 3.5 Threat of Substitutes 4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis by Regions 4.1 Benign Prostatic Hyperplasia (BPH) Drugs Overall Market: 2023 VS 2024 VS 2030 4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast Analysis (2019-2030) 4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Region (2019-2024) 4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2025-2030) 5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type and Application 5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application 6 North America 6.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate Analysis (2019-2030) 6.2 North America Key Manufacturers Analysis 6.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type 6.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application 6.5 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country 6.5.1 US 6.5.2 Canada 7 Europe 7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate Analysis (2019-2030) 7.2 Europe Key Manufacturers Analysis 7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type 7.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application 7.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country 7.5.1 Germany 7.5.2 France 7.5.3 United Kingdom 7.5.4 Italy 7.5.5 Spain 7.5.6 Benelux 8 China 8.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate Analysis (2019-2030) 8.2 China Key Manufacturers Analysis 8.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type 8.4 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application 9 APAC (excl. China) 9.1 APAC (excl. China) Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate Analysis (2019-2030) 9.2 APAC (excl. China) Key Manufacturers Analysis 9.3 APAC (excl. China) Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type 9.4 APAC (excl. China) Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application 9.5 APAC (excl. China) Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country 9.5.1 Japan 9.5.2 South Korea 9.5.3 India 9.5.4 Australia 9.5.5 Indonesia 9.5.6 Vietnam 9.5.7 Malaysia 9.5.8 Thailand 10 Latin America 10.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate Analysis (2019-2030) 10.2 Latin America Key Manufacturers Analysis 10.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type 10.4 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application 10.5 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country 10.5.1 Mecixo 10.5.2 Brazil 11 Middle East & Africa 11.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate Analysis (2019-2030) 11.2 Middle East & Africa Key Manufacturers Analysis 11.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type 11.4 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application 11.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country 11.5.1 Saudi Arabia 11.5.2 South Africa 12 Market Competition by Manufacturers 12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Revenue by Key Manufacturers (2020-2024) 12.2 Benign Prostatic Hyperplasia (BPH) Drugs Competitive Landscape Analysis and Market Dynamic 12.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Competitive Landscape Analysis 12.2.2 Global Key Manufacturers Headquarter and Key Area Sales 12.2.3 Market Dynamic 13 Key Companies Analysis 13.1 Eli Lilly 13.1.1 Eli Lilly Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.2 GlaxoSmithKline 13.2.1 GlaxoSmithKline Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.3 Astellas Pharma 13.3.1 Astellas Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.4 Sanofi 13.4.1 Sanofi Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.5 Abbott 13.5.1 Abbott Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.5.2 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.5.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.6 Pfizer 13.6.1 Pfizer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.6.2 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.6.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.7 TEVA 13.7.1 TEVA Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.7.2 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.7.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.8 Allergan 13.8.1 Allergan Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.8.2 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.8.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.9 Mylan 13.9.1 Mylan Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.9.2 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.10 Novartis 13.10.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.10.2 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 13.11 Merck 13.11.1 Merck Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio 13.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024) 14 Industry Chain Analysis 14.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Analysis 14.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Raw Material and Suppliers Analysis 14.2.1 Upstream Key Raw Material Supply Analysis 14.2.2 Raw Material Suppliers and Contact Information 14.3 Benign Prostatic Hyperplasia (BPH) Drugs Typical Downstream Customers 14.4 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channel Analysis 15 Research Findings and Conclusion 16 Methodology and Data Source 16.1 Methodology/Research Approach 16.2 Research Scope 16.3 Benchmarks and Assumptions 16.4 Date Source 16.4.1 Primary Sources 16.4.2 Secondary Sources 16.5 Data Cross Validation 16.6 Disclaimer
Publisher: DIResearch
Related Reports
- Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Online Pharmacy Market (2024 Edition): Analysis By Drug Type (Over the Counter (OTC) Drugs, Prescription Drugs, Others), By Platform, By Product Type, By Region: Market Insights and Forecast (2020-2030)
- Global Diagnostic X-rays Market (2024 Edition): Analysis By Type (General Radiography, Angiography, Surgical Fluoroscopy, Mobile X ray, Other Types), By End Users, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Diagnostic Labs Market (2024 Edition): Analysis By Testing Services (Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, and Others), By Lab Type, By Application: Market Insights and Forecast (2020-2030)
- Lateral Flow Assays Market By Product Type (Lateral Flow Readers {Digital/Mobile Readers and Benchtop Readers} and Kits and Reagents), By Application (Clinical Testing {Pregnancy Testing, Influenza Testing, Tuberculosis, D-Dimer Testing, and Other Clinical Testing}, Drug Abuse Testing, Veterinary Diagnostics, Food Safety & Environmental Testing, and Other Applications), By Technique (Sandwich Assay, Competitive Assay, and Multiplex Assay), By End-User (Home Care, Hospitals and Clinics, and Other End Users), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support